Tumor-derived exosome immunocapture and RNA extraction kit (10 reactions) (BN00080)

(No reviews yet) Write a Review
SKU:
BN00080
  • Tumor-derived exosome immunocapture and RNA extraction kit (10 reactions) (BN00080)
  • Tumor-derived exosome immunocapture and RNA extraction kit (10 reactions) (BN00080)
  • Tumor-derived exosome immunocapture and RNA extraction kit (10 reactions) (BN00080)
€936

Description

ELISA Kit Technical ManualMSDS

Tumor-derived exosome immunocapture and RNA extraction kit (10 reactions)

Exosomes are small endosome derived lipid nanoparticles (50-120 nm) actively secreted by exocytosis by most living cells. Exosome release occurs either constitutively or upon induction, under both normal and pathological conditions, in a dynamic, regulated and functionally relevant manner. Both the amount and molecular composition of released exosomes depend on the state of a parent cell. Exosomes have been isolated from diverse cell lines (hematopoietic cells, tumor lines, primary cultures, and virus infected cells) as well as from biological fluids in particular blood (e.g. serum and plasma from cancer patients) and other body fluids (broncho alveolar lavage fluid, pleural effusions, synovial fluid, urine, amniotic fluid, semen, saliva etc). Exosomes have pleiotropic physiological and pathological functions and an emerging role in diverse pathological conditions such as cancer, infectious and neurodegenerative diseases. Exosomes shuttle functional RNA molecules in the target cell. Increasing evidence suggests a role for exosome-derived miRNAs in the development and/or progression of specific human diseases. Pathogenic miRNAs might be exploited as novel therapeutic targets or disease biomarkers in complex diseases, including cancer. In fact, miRNAs seem to play critical roles as transcriptional and post-transcriptional regulators of epigenetic mechanisms and cell processes and have been linked to the etiology, progression and prognosis of cancer. Similar miRNA expression patterns between tumor tissue samples and circulating exosomes have been observed. Tumor-derived exosome RNA extraction kit has been developed for the efficient enrichment of tumor-specific exosome population and RNA extraction from human biofluids and vesicle associated RNAs. Exosome capture occurs on immunobeads pre-coated with exosome associated antibodies enabling for tumor-derived exosome enrichment. The captured exosomes are subsequently lysed with an optimized lysis buffer and total RNA is purified using spin columns with a fast and user-friendly process. Eluted RNA can be used for downstream analyses or stored at -80°C. Exosome standards for positive control are also included in the kit. All our kits guarantee high specificity for exosomal RNA and high yield of total RNA (including small RNAs) than similar products.

Figure: 1) Expected Nanodrop profile for RNA extracted from immunocaptured exosomes (100 μl of human plasma). Yield = 8.4 ng/μl; A 260/280 =1.6; A260/230= 1.85. 2) Nanodrop quantification of total RNA yield. 3) miRNA 21 amplification by qPCR. 4) Enrichment in miRNA-21 expression level in cancer when TumorExoRNA kit is used. 5) Enrichment in miRNA-16 expression level in cancer when TumorExoRNA kit is used

Key Information Description

Detection Method

Tumor Exosome immunocapture and RNA extraction

Species Reactivity

Human biological fluids including Plasma, Serum, Urine and Cell culture media.

Applications

N/A

Features and Benefits

High yield of total RNA (including small RNAs)

Kit Components

  • Pre-couple latex immunobeads
  • Bead Washing buffer (5X)
  • Lysis buffer RNA
  • Washing buffer (to add Ethanol 96%)
  • Elution buffer
  • Columns
  • RNase free elution tubes (1.5 ml)
  • Lyophilized Exosome Standard

Storage Conditions

4°C

Shipping Conditions

Gel Pack

USAGE

For Research Use Only! Not For Use in Humans.

View AllClose